Can Remicade (infliximab) cause elevated serum iron and increased red blood cell distribution width in a male patient?

Remicade Does Not Directly Cause High Iron or Elevated RDW—But It Can Induce Functional Iron Deficiency That Paradoxically Elevates RDW

Remicade (infliximab) does not cause elevated serum iron levels; instead, it increases functional iron deficiency, which typically manifests as elevated RDW and low serum iron. The elevated RDW you're observing is likely a marker of the underlying inflammatory disease activity or the functional iron deficiency induced by infliximab treatment itself 1.

Understanding the Mechanism

Infliximab treatment creates a paradoxical situation with iron metabolism:

• Infliximab significantly increases erythropoietin (EPO) and soluble transferrin receptor (sTfR) levels, which reflects increased erythropoietic drive and functional iron deficiency 1
• This functional iron deficiency occurs even when iron stores may appear adequate, because inflammation prevents proper iron utilization
• The result is elevated RDW (reflecting increased variation in red blood cell size) rather than elevated serum iron 1, 2

What the Lab Findings Actually Mean

Elevated RDW in IBD Patients on Remicade:

• RDW is independently elevated in active inflammatory bowel disease, with levels significantly higher in active disease versus remission (mean difference 1.29% in Crohn's disease, p<0.001) 3
• An RDW cut-off >14% shows 86% sensitivity and 78% specificity for detecting active Crohn's disease 3
• RDW >14.5% yields 78.9% sensitivity and 76.3% specificity for objective endoscopic disease activity 2
• Each 1% increase in RDW independently predicts active disease (adjusted OR 1.65), even in non-anemic patients 2

Regarding Serum Iron:

• High serum iron would be unusual with Remicade treatment—the expected pattern is functional iron deficiency with LOW serum iron, low transferrin saturation, and elevated sTfR 1
• If serum iron is truly elevated, consider alternative explanations unrelated to infliximab (hemochromatosis, recent iron supplementation, hemolysis, or laboratory error)

Clinical Approach to This Patient

Step 1: Verify the iron elevation is real

• Repeat fasting serum iron, transferrin saturation, and ferritin
• Check for hemolysis markers if appropriate
• Ensure no recent oral/IV iron supplementation

Step 2: Assess for functional iron deficiency despite any apparent iron elevation

• Measure soluble transferrin receptor (sTfR) if available
• Check ferritin (though remember it's an acute phase reactant and may be falsely normal/elevated in inflammation) 4
• In the context of inflammation, ferritin <45 μg/L suggests iron deficiency, while >150 μg/L makes absolute iron deficiency unlikely 4

Step 3: Evaluate disease activity

• The elevated RDW itself indicates likely active inflammatory disease 2, 3
• Correlate with C-reactive protein, fecal calprotectin, and clinical symptoms
• Consider endoscopic evaluation if disease activity is suspected

Step 4: Address the functional iron deficiency

• Intravenous iron sucrose is safe when combined with infliximab and effectively restores the functional iron deficiency induced by infliximab 1
• After 12 weeks of combined IV iron and infliximab treatment, EPO and sTfR levels drop significantly (p<0.001 for both) 1
• Optimize IBD therapy first, as infliximab itself improves hemoglobin levels when disease activity is controlled 5

Common Pitfalls to Avoid

1. Don't assume elevated RDW is simply from iron deficiency anemia—it's an independent marker of inflammatory disease activity in IBD 2, 3

2. Don't rely solely on ferritin in inflammatory states—it can be falsely elevated as an acute phase reactant, masking true iron deficiency 4

3. Don't withhold IV iron due to concerns about combining it with infliximab—the combination is safe with only 2.3% mild infusion reactions in studied patients 1

4. Don't ignore the RDW elevation—it provides incremental diagnostic value beyond CRP alone (AUC improves from 0.845 to 0.880 when RDW is added, p=0.002) 2

Hematologic Monitoring on Remicade

The FDA label warns that leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with Remicade 6. Patients should be advised to seek immediate medical attention for signs of blood dyscrasias or persistent fever, and discontinuation should be considered if significant hematologic abnormalities develop 6.

However, elevated serum iron is not a recognized adverse effect of infliximab—the expected pattern is functional iron deficiency with low iron availability for erythropoiesis 1.